natgillin/translations-raw huggingface dataset:
Computer program product for enhancing the usable bandwidth between on the one hand an access point (15) of a radio access network (16) of a telecommunications network (10) and on the other hand a User Equipment (20), the computer program product comprising a computer program stored on a storage medium, the computer program comprising program code which, when executed on a antenna device means of the system according to claim 10, causes the system to perform a method according one of claims 1 to 9. 
14. Računalni programski proizvod za povećanje raspoloživog frekventnog opsega između, sjedne strane, pristupne točke (15) pristupne radio mreže (16) telekomunikacijske mreže (10) 1, s druge strane, korisničke opreme (20), pri čemu računalni programski proizvod sadrži računalni program koji je smješten na mediju za čuvanje podataka, a računalni program sadrži programski kod koji, kada se izvršava na računalu, prouzrokuje da računalo izvršava postupak prema jednom od zahtjeva od 1 do 6.
The method of clause 1, wherein said formulation further comprises an anti-inflammatory agent, an anesthetic, an adhesion facilitator, a permeability or penetration enhancer, a bioadhesive, a hygroscopic agent, an ear wax softener, or a preservative. 
Formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži protuupalno sredstvo, anestetik, pojačivač prianjanja, pojačivač propusnosti ili prodornosti, bioadheziv, higroskopno sredstvo, omekšivač ušnog voska, ili konzervans.
The examples demonstrate that the compositions of the invention achieve a reduction in disease incidence and disease severity in an animal model of uveitis and so they may be useful in the treatment or prevention of uveitis. 
Pripravak prema zahtjevu 2, naznačen time da je pripravak za upotrebu u postupku liječenja ili prevencije uveitisa, i pri čemu je pripravak za upotrebu u postupku smanjenja ili prevencije oštećenja retine kod uveitisa.
the pharmaceutical composition is free of trypsin; and/or 
(b) farmaceutski sastav je bez tripsina; i/ili
A process according to Claim 6. characterized in that the particle size of the copper sulfate pentahydrate applied is in 95 % under 0.2 mm. 
Postupak u skladu sa zahtjevom 6, naznačen time, što se veličina čestice bakar sulfat pentahidrata primjenjuje u 95% ispod 0,2 mm. t>&
stirring the suspension at a temperature of 5 to 25 °C, preferably 10 to 15 °C for 30 min to 2 hours, preferably 30 min to 1 hour, such as about 45 min; and 
(b) miješanje suspenzije na temperaturi od 5 do 25*C, poželjno od 10 do 15*C za vrijeme od 30 min do 2 sata, poželjno od 30 min do 1 sata, naime oko 45 min; i
is crush resistant and has a breaking strength of at least about 439 N; 
mg oksikodon hidroklorida; i pri čemu pripravak sadrži barem oko 65 % (težinski) polietilen oksida.
The ground engaging apparatus (10) of Claim 7 wherein at least one of said outer end surfaces has a noncircular drive opening extending inwardly therethrough. 
Sklop (16) spojnog klina prema Zahtjevu 1 gdje: najmanje jedna od navedenih vanjskih krajnjih površina posjeduje nekružni otvor za vođenje izveden kroz nju prema unutra.
The ophthalmic formulation of claim 5, wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of nepafenac, bromfenac, and meloxicam. 
Oftalmička formulacija prema zahtjevu 8, naznačena time što je ne-steroidni anti-upalni lijek odabran iz skupine koja se sastoji od nepafenaka i meloksikama.
List of reference signs: 
Popis referentnih oznaka 1
A compound according to claim 1 selected from the group consisting of -[1-(2-fluorobenzyl)-3-methylpyrrolidin-3-yl]-1 H -benzimidazole-4-carboxamide; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran Iz skupine koja se sastoji od 2-[1-(2-fuorobenzil)-3-metilpirolidin-3-11]-1H-benzimidazol-4-karboksamida;
Embodiment 4. The pharmaceutical composition of embodiment 1 wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCI at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 10 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaC1 1 63 mM FCI, pri pH 1,21 na 37%.
The aerosol for use of claim 1 or claim 2, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum and iron. 
Aerosol za uporabu sukladno patentnom zahtjevu 1 ili patentnog zahtjeva 2, pri čemu se dvovalentni ili trovalentni kation odabire iz magnezija, kalcija, cinka, bakra, aluminija i željeza.
The method of claim 8, wherein the intravaginal ring is replaced after about 7 days following administration to the patient. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 7, naznačen time, da se intravaginalni prsten zamjenjuje 7 dana nakon primjene na pacijentici.
The crystalline form of SAG according to claim 1, further characterised by an X-ray powder diffraction spectrum also having characteristic peaks, expressed in degrees 2-theta [°], at 20.4, 21.1, 25.1, 25.7, 27.0, 27.6, 27.9, 32.7 ± 0.2. The crystalline form A of SAG according to claims 1 and 2, characterised by an IR spectrum, obtained in a potassium bromide matrix, with characteristic absorption bands at 3344, 1726, 1687 and 1663 cm-1, inter alia. 
Kristalinični oblik SAG prema patentnom zahtjevu 1, dalje naznačeno time da rentgenski difraktogram praška također ima karakteristične signale, izražene u stupnjevima 2-theta ["], pri 20.4, 21.1, 25.1, 25.7, 27.0, 27.6, 27.9, SAG kristaliničnog oblika A prema patentnim zahtjevima 1 i 2, naznačeno time da je IR spektar, dobiven u malrici kalijeva bromida, s karakterističnim apsorpcijskim vrpcama među ostalima pri 3344, 1726, 1687 i 1663 cm .
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound bixafen. 
(i), NN CH, naznačen time da je Ry difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
the mature type I elastase is a mature human type I elastase, which optionally comprises an amino acid sequence which has: 
(b) zreli tip I elastaze je zreli humani tip I elastaze, koji opcionalno sadrži sekvencu aminokiseline koja ima:
In some embodiments, the optically transparent member comprises a semipermeable member, and the continuously maintaining a dead zone is carried out by feeding an inhibitor of polymerization through the optically transparent member, thereby creating a gradient of inhibitor in the dead zone and optionally in at least a portion of the gradient of polymerization zone. 
Postupak prema zahtjevu 1, naznačen time da navedeni optički transparentni element sadrži polupropusni element, koji navedeni element kontinuirano održava mrtvu zonu što se provodi dodavanjem inhibitora polimerizacije kroz navedeni optički transparentni element, čime se stvara gradijent inhibitora u navedenoj mrtvoj zoni i po izboru u barem jednom dijelu navedenog gradijenta zone polimerizacije.
A compound, comprising a peptide and a conjugating group, wherein the peptide comprises an amino acid sequence having the formula: EPMATHMARKEREP wherein 
Spoj koji sadrži peptid i konjugiranu skupinu, pri čemu peptid sadrži sekvencu aminokiseline:
A method of facilitating processing in a computing environment, said method comprising: providing by a host operating system to a guest operating system an indication of installation of a warning track facility within the computing environment, the indication of installation to be obtained by the guest operating system, and the warning track facility to provide to the guest operating system a grace period to perform a first function; 
osiguravanju od strane ugošćujućeg operativnog sustava gostujućem operativnom sustavu indikacije o instaliranju sredstva s upozoravajućim tragom u računalnom okolišu, gdje gostujući operativni sustav treba dobiti indikaciju o instaliranju, a sredstvo s upozoravajućim tragom treba osigurati gostujućem operativnom sustavu razdoblje počeka kako bi proveo prvu funkciju;
An oral transmucosal composition comprising a therapeutically effective amount of insulin, an effervescent excipient component; and a bile salt for use in a method of treating diabetes in a recipient in need thereof. 
Oralni transmukozni pripravak naznačen time da sadrži terapeutski učinkovitu količinu inzulina, komponentu šumeće pomoćne tvari i žučnu sol za upotrebu u postupku liječenja dijabetesa kod primatelja kojemu je potreban. t>&
wherein the terpene oil content is the additive content of the terpenes in the terpene profile, wherein the terpene profile consists of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene of the plant, and wherein the cannabinoid and terpene contents are measured by GC-FID and calculated based on weight of the extract, wherein extracts comprising a), b), c), and d) are obtainable from a plant comprising the inflorescence of claim 1. 
gdje je sadržaj terpenskog ulja aditivan sadržaj terpena u terpenskom profilu, gdje se terpenski profil sastoji od terpinolena, a-felandrena, B-ocimena, karena, limonena, Y-terpinena, a-pinena, a-terpinena, B-pinena, fenhola, kamfena, a-terpineola, a-humulena, B-kariofilena, linaloola, kariofilen-oksida, te mircena of the biljka, te gdje se sadržaje kanabinoida i terpena mjeri uz pomoć GC-FID, te izračunava na osnovi težine ekstrakta, gdje se ekstrakte koji sadrže a), b), c), te d) može dobiti iz biljke koja sadrži inflorescenciju u skladu s patentnim zahtjevom 1.
Preferably, the oscillating movement of the first oscillating device is linear. 
(32) Datum podnošenja prve prijave: 13.05.2011.
binding polypeptide according to claim 1, wherein X3 is selected from I, L and V. 
Polipeptid koji veže C5 sukladno zahtjevu 1, pri čemu je X3 odabran od I, L i V.
coding a significant coefficient flag representing a location of a second significant transformation coefficient; and generating a bitstream including the information about a location of the last significant transformation coefficient and the significant coefficient flag of the second significant transformation coefficient; 
dekodiranje indikatora značajnog koeficijenta koji se nalazi u primljenom toku bitova, što predstavlja lokaciju drugog značajnog koeficijenta transformacije; te dekodiranje drugog značajnog koeficijenta transformacije primjenom indikatora značajnog koeficijenta;
The 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to claims 1-8 wherein X is O. 
Derivat 4-fenil-5-okso-1,4,5,6,7,8-heksahidrokinolina u skladu s patentnim zahtjevima 1-8, gdje X je O.
for use in a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one chemical entity. 
Barem jedan kemijski entitet i barem jedna farmaceutski prihvatljiva pomoćna tvar za upotrebu prema zahtjevu 8, gdje je spomenuta bolest, poremećaj ili medicinsko stanje poremećaj spavanja sekundaran depresiji.
is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, alkylaryl or substituted alkylaryl; 
je vodik, alkil ili supstituirani alkil, alkenil ili supstituirani alkenil, alkinil ili supstituirani alkinil, cikloalkil ili supstituirani cikloalkil, cikloalkenil ili supstituirani cikloalkenil, heterocikl ili supstituirani heterocikl, aril ili supstituirani aril, alkilaril ili supstituirani alkilaril;
Disclosed herein is a pharmaceutical composition comprising or consisting essentially of a combination of an amount of a GPR119 agonist and an amount of a DPP-IV inhibitor, together with at least one pharmaceutically acceptable carrier. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da pripravak je farmaceutski pripravak koji sadrži GPR119 agonist i DPP-IV inhibitor skupa s barem jednom farmaceutski prihvatljivom podlogom. .
or a heteroaromatic group, substituted or unsubstituted by one or more halogen atoms, or by one or more C1-C6 alkyl groups, or by one or more C1-C6 alcoxy groups, or by a cyano group. 
- ili heteroaromatska skupina, supstituirana ili nesupstituirana s jednim ili više atoma halogena ili jednom ili više C-Cg-alkilnih skupina ili jednom ili više C,-Cg-alkoksilnih skupina ili cijano-skupinom.
In one embodiment the antibody of the teaching is coupled to a therapeutic agent such as a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži protutijelo sukladno patentnom zahtjevu 1 spojeno s terapeutskim sredstvom, pri čemu je terapeutsko sredstvo poželjno toksin, radioizotop, lijek ili citotoksično sredstvo.
A pharmaceutical composition, comprising a therapeutically effective amount of the compound of formula (I), or a tautomer, mesomer, raceme, enantiomer, diastereomer, and mixture thereof, and a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, koji sadrži terapeutski učinkovitu količinu spoja formule (I), ili njegov tautomer, mezomer, racemat, enantiomer, dijastereomer i smjese, i njegovu farmaceutski prihvatljivu sol sukladno bilo kojem od patentnih zahtjeva 1 do 12, i farmaceutski prihvatljiv nosač.
The compound for use of claim 4 where the B-amyloid disease is selected from the group of diseases consisting of Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, and cerebral B-amyloid angiopathy. 
Spoj za uporabu prema zahtjevu 4 naznačen time da je fB-amiloidna bolest odabrana iz skupine bolesti koja se sastoji od Alzheimerove bolesti, Downovog sindroma, nasljednog cerebralnog krvarenja s amiloidozom - nizozemski tip, te cerebralne B-amiloidne angiopatije.
Particularly if the patient has liver metastasis. 
Posebno ako pacijent ima jetrene metastaze.
Source of starting materials 3-chloropropanoyl chloride and ethyl cyanoacetate were obtained commercially from Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT, United Kingdom, or synthesised by standard methods (see, for example, Schankt, Kurt, Liebigs Ann. 
Izvor polazišnih materijala 3-kloropropanoil klorid i etil cijanoacetat dobiveni su komercijalno od Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT, Ujedinjeno kraljevstvo, ili sintetizirani standardnim metodama. a-bromo-p-nitro-acetofenon 7 dobiven je bromiranjem p-nitroacetofenona s bromom u tetrahidrofuranu (THF).
In any case, by sensing the amount of water supplied to the thermoblocks a defined amount of water can be passed trough the thermoblocks in order to produce a defined amount of hot water, beverage and/or steam. 
U svakom slučaju, praćenjem količine vode koju se dovodi u termoblokove kroz termoblokove može se propustiti definirana količina vode kako bi se dobilo željenu količinu vruće vode, napitka i/ili vodene pare.
A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier diluent, or excipient, for use in therapy. 
Ljudsko modificirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačeno time što je namijenjen upotrebi u terapiji.
a second polynucleotide encodes a protein of interest and whereby the protein of interest and the protein having an amino acid sequence comprising ceramide transfer protein CERT or a derivative or mutant thereof are expressed by said cell, whereby said derivative is a polypeptide molecule which is at least 70% identical in sequence with the original CERT sequence or its complementary sequence or said derivative is a homologous CERT sequence from a different organism and whereby said mutant is based on targeted modification of CERT sequences by substitution, insertion or deletion of one to ten amino acids. 
drugi polinukleotid kodira korisni protein, te se pritom vrši ekspresija iz spomenute stanice za korisni protein i protein s amino-kiselinskom sekvencom, koja sadrži ceramidni prijenosni protein CERT ili njegov derivat ili njegov mutant, gdje spomenuti derivat je polipeptidna molekula koja je barem 70% istovjetna u sekvenci s originalnom CERT-sekvencom ili njenom komplementarnom sekvencom ili je spomenuti derivat homologna CERT-sekvenca iz različitog organizma i pri čemu je spomenuti mutant baziran na ciljanoj modifikaciji CERT-sekvenci pomoću zamjene, umetanja ili izbacivanja od jedne do deset amino kiselina.
Generator according to claim 1-3, wherein the parts of the column, the inlet and the outlet are coated with a iron-free material and/or are made from a iron-free material, preferably metal free material. 
Generator prema zahtjevu 1 ili 2, naznačen time da dijelovi kolone, ulazni i izlazni otvor su prevučeni sa materijalom bez željeza i/ili su izrađeni od materijala bez željeza, poželjno materijalom bez metala.
A process for preparing a vaccine composition, the process comprising preparing an antigen against Haemophilus influenzae type b (Hib) according to the method of claim 1, 
- a) se antigen protiv Haemophilus influenzae tip b (Hib), koji sadrži kapsularni polisaharid (PRP), na industrijskoj razini, priprema u skladu s postupkom prema zahtjevu 1,
The firearm of one of claims 1 - 3, wherein the first angled surface of the mobile mass forms an angle of between about 10 degrees and about 70 degrees with respect to a line perpendicular to the longitudinal axis of the barrel. 
Vatreno oružje iz patentnih zahtjeva 1-7, pri čemu prva kutna površina pomične mase (34) tvori kut otprilike od 10 stupnjeva i otprilike od 70 stupnjeva u odnosu na liniju okomitu na uzdužnu os spremnika (21).
To provide a method for manufacturing an oxazole compound or salts thereof represented by the general formula (1): 
Postupak za proizvodnju oksazolnog spoja ili njegove soli prikazanog općom formulom (1):
The arrester according to claim 18, characterized in that the strip is helically wound around a surface of a cylindrical hollow component. 
Gromobran u skladu s patentnim zahtjevom 18, naznačen time što je traka spiralno namotana oko površine valjkaste šuplje komponente.
Currently, Fibra-Cel® disks and microcarriers are not re-used. 
Trenutačno, diskovi Fibra-Cel* se ne rabe ponovno te.
A nitrogen-containing heterocyclic compound represented by Formula (I): (wherein, in Formula (I), R represents a group represented by CR1R2R3, an unsubstituted or substituted C6-10 aryl group, or a cyano group; 
Heterociklički spoj koji sadrži dušik, njegova sol, ili njegov N-oksidni spoj, prema zahtjevu 1, naznačen time što, u Formuli (11), R predstavlja skupinu prikazanu s CR'R*R',
Application of a pressure media external to the borehole then entails expansion of both bolts 7 ′ and 7 ″. 
Primjena tlačnog medija izvana na bušotinu ima za posljedicu ekspanziju oba sidra 7'i 7".
An antibody or antigen-binding fragment or pharmaceutical composition according to one or more of items 38 to 40, wherein the use in medicine is the use in a method for the treatment of inflammatory bowel disease. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja upalne bolesti crijeva.
The compound according to claim 11, selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 6, naznačen time što se bira iz skupine koju čine:
The heat transport system of claim 3, wherein the heat transport system comprises at least one thermoelectric heat pump arranged to receive heat from the fluid conduit and transport heat to the reject heat exchanger, and the at least one thermoelectric heat pump is operated responsive to the temperature of the chamber or surface. 
Sustav prijenosa topline prema zahtjevu 4, naznačen time, da sustav prijenosa topline obuhvaća najmanje jednu termoelektričnu toplinsku pumpu namještenu za primanje topline iz fluidnog cjevovoda i za prijenos topline do povratnog izmjenjivača topline, te time, da najmanje jedna termoelektrična toplinska pumpa radi u skladu s reakcijom na temperaturnu vrijednost u komori ili na površini.
isolating and crystallizing a salt having formula VII wherein R is a protecting group and A- is an anion; 
Vi) DA, "NK OH gdje R je zaštitna skupina i A- je anion;
is hydrogen, alkyl, alkenyl, or alkynyl, or R8 and R9 in combination form oxo or oxime; and each of R10 is independently selected from the group consisting of hydrogen, fluoro, chloro, hydroxy, alkyl, and heteroalkyl with the proviso that when R10 is hydroxy, n is 1 or 2;or two R10 and the carbon atom(s) they are attached to form a 3- to 8-membered cycloalkyl or heterocycloalkyl. 
Ro je vodik, nesupstituirani alkil, nesupstituirani alkenil ili nesupstituirani alkinil; ili Rz 1 Ry zajedno tvore okso ili oksim; i svaki od Ryo je neovisno odabran iz skupine koja se sastoji od vodika, fluora, klora, hidroksi i nesupstituiranog alkila; ili dva Ryo i ugljikov(i) atom(i) na koje su oni priključeni, tvore 3-člani do 8-člani nesupstituirani cikloalkila ili nesupstituirani heterocikloalkil.
(A2b) a halogen-substituted phenyl group); and n represents an integer of 1 to 6. 
(A2b) halogen-supstituiranu fenilnu skupinu); a n predstavlja cijeli broj od 1 do 6.
As mentioned above, the present invention, i.a., provides a novel composite material useful for applications where volumetric shrinkage upon curing of the material is undesirable or even prohibitive. 
Kao što je gore spomenuto, ovaj izum prikazuje nove kompozitne materijale korisne za primjenu gdje je volumetrijsko skupljanje nakon očvršćivanja materijala nepoželjno ili čak zabranjeno.
A method according to claim 1 or 2 characterised in that (+)- O, O' -di- p -toluoyl-(S,S)-tartaric acid is used. 
Postupak prema zahtjevu 1 ili 2, naznačen time što se upotrebljava (+)-0,0"-di-p-toluoil-(S,S)-vinska kiselina.
An assembling/splicing of the completed product is only partially necessary or not necessary at all. 
Sklapanje/spajanje dovršenog proizvoda je potrebno samo djelomično ili uopće nije potrebno.
The filter module according to claim 1, wherein an area of the second section is about 10% to 30% of an area of the first section. 
Pročistač zraka sukladno jednom od prethodnih zahtjeva 9 do 12, koji se dalje sastoji od ventilatora (2) koji je postavljen neposredno uz filtarski modul (1).
After a 20-day adaptation phase, growth of the cells is very consistent and reproducible in the serum-free medium. 
Nakon 20-dnevne faze prilagodbe, rast stanica je konzistentan i reproducibilan u mediju bez seruma.
In this embodiment, the high pressure product gas stream 198 is recycled to the adsorbent stage of the TSA unit 100. 
što se navedenu struju drugog plinovitog proizvoda pod visokim tlakom reciklira u navedeni sloj ugljičnog adsorbensa od navedene jedinice TSA.
The reaction mixture is stirred at ambient temperature for 40 minutes. 
Reakcijsku smjesu se miješa 40 minuta pri sobnoj temperaturi.